Novartis has officially transitioned into a pure-play innovative medicines company, marking a significant shift following the recent spin-offs of Alcon and Sandoz. As a result, the...
Novartis, the Swiss pharmaceutical giant, is reportedly in advanced negotiations to acquire Avidity Biosciences, a U.S.-based biotechnology company, for more than $70 per share. This information...
As the deadline set by the Trump administration approaches, Novartis CEO Vas Narasimhan has indicated that the company is contemplating reducing drug prices in the United...
